The primary purpose of this study is to estimate the percentage of participants in the
population considered clinically as not having pulmonary hypertension (PH) that are positive
for PH biomarker (micro ribonucleic acid [RNA]); estimate the percentage of participants in
the population considered clinically as not having PH that are positive for PH by cardiac
magnetic resonance imaging (MRI) and compare results of the MRI to the biomarker results; to
determine the performance of the biomarker signatures identified in the CIPHER (NAPUH0001)
study in terms of sensitivity, specificity, positive predictive value (PPV) and negative
Oral selexipag is commercially available in several countries for the treatment of a
particular group of pulmonary hypertension (PH) called pulmonary arterial hypertension (PAH).
The aim of the present study is to investigate whether selexipag could be helpful to treat
patients with another form of PH called sarcoidosis-associated pulmonary hypertension (SAPH).
IMPAHCT: Inhaled iMatinib Pulmonary Arterial Hypertension Clinical Trial is a Phase 2b/Phase
3 study to evaluate the safety and efficacy of AV-101 (dry powder inhaled imatinib) in
patients with Pulmonary Arterial Hypertension (PAH). The Phase 2b part of the study will
assess three doses to establish an optimal dose for the Phase 3 part of the study. The Phase
2b primary endpoint will be the placebo corrected change in pulmonary vascular resistance
(PVR). The Phase 3 primary endpoint will be the placebo corrected change in 6-minute walk
distance (6MWD) after 24 weeks of treatment.
A Randomized, Placebo-Controlled, Double-blind, Dose Escalation Study to Assess Safety,
Efficacy and Pharmacokinetics of GMA301 Injection in Subjects with Pulmonary Arterial
The purpose of this study is to evaluate the effect of macitentan on hemodynamic measures at
Week 24 in pediatric populations.
The purpose of the study is to evaluate the change from baseline to 12 months after study
enrollment in the number of the following non-invasive risk criteria: World Health
Organization Functional Class (WHO/FC), 6-minute walk distance (6MWD), Brain Natriuretic
Peptide (BNP) or N-terminal pro-brain Natriuretic Peptide (NT-proBNP).
Study ROR-PH-302, ADVANCE CAPACITY, is designed to evaluate the effects of ralinepag therapy
on exercise capacity as assessed by change in peak oxygen consumption (VO2) derived from
cardiopulmonary exercise testing (CPET) after 28 weeks of treatment
The purpose of this study is to describe the time to all-cause death and time to death due to
pulmonary arterial hypertension (PAH) or first hospitalization due to PAH in the overall
study population and within each cohort.
The purpose of this study is to assess the safety and efficacy of Rodatristat Ethyl in
pulmonary arterial hypertension (PAH) patients.
The purpose of this study is to evaluate whether the addition of selexipag to standard of
care treatment delays disease progression in children with Pulmonary Arterial Hypertension
(PAH) in comparison to placebo.